COR Cortex Pharmaceuticals,

First graph, first sentence should read: Cortex Pharmaceuticals, Inc. (AMEX: COR, http://www.cortexpharm.com), Chairman, President and CEO, Roger G. Stoll, PhD, will speak at the 20th Annual Roth Capital Partners Growth Stock Conference to be held at The Ritz-Carlton Laguna Niguel Hotel located in Dana Point, California. (sted Cortex Pharmaceuticals, Inc. (AMEX: COR, http://www.cortexpharma.com), Chairman, President and CEO, Roger G. Stoll, PhD, will speak at the 20th Annual Roth Capital Partners Growth Stock Conference to be held at The Ritz-Carlton Laquna Nigel Hotel located in Dana Point, California.) The corrected release reads: CORTEX�S CEO TO PRESENT AT THE ROTH CAPITAL PARTNERS 20TH ANNUAL ORANGE COUNTY CONFERENCE Cortex Pharmaceuticals, Inc. (AMEX: COR, http://www.cortexpharm.com), Chairman, President and CEO, Roger G. Stoll, PhD, will speak at the 20th Annual Roth Capital Partners Growth Stock Conference to be held at The Ritz-Carlton Laguna Niguel Hotel located in Dana Point, California. Dr Stoll will present in the Promenade Room on Tuesday, February 19, 2008 at 2:30 pm PST (5:30 pm EST). The conference will feature over three hundred small-cap growth companies across a broad spectrum of sectors, including technology, healthcare, financial services, and consumer products. Dr. Stoll will provide a comprehensive update on Cortex�s 2008 corporate objectives and milestones, including an update on the progress with its lead low impact AMPAKINE� product candidate, CX717, as a novel treatment for respiratory depression, as well as on other scientific and corporate developments. A live webcast of the presentation can be accessed by logging onto http://www.wsw.com/webcast/roth16/cor/. A replay will be available for thirty days following the conference. More information regarding the conference can be found at http://www.rothconference.com/. About Cortex Cortex, located in Irvine, California, is a neuroscience company focused on novel drug therapies for neurological and psychiatric disorders. The Company is pioneering a class of proprietary pharmaceuticals called AMPAKINE� compounds, which act to increase the strength of signals at connections between brain cells. The loss of these connections is thought to be responsible for memory and behavior problems in Alzheimer�s disease. Many psychiatric diseases, including schizophrenia, occur as a result of imbalances in the brain�s neurotransmitter system. These imbalances may be improved by using the AMPAKINE technology. Cortex has alliances with N.V. Organon for the treatment of schizophrenia and depression and with Les Laboratoires Servier for the development of AMPAKINE compounds to treat the neurodegenerative effects associated with aging and disease, including Mild Cognitive Impairment, Alzheimer�s disease and anxiety disorders. For additional information regarding Cortex, please visit Cortex Pharmaceuticals� Website at www.cortexpharm.com. Forward-Looking Statement Note - This press release contains forward-looking statements concerning the Company's research and development activities. The success of such activities depends on a number of factors, including the risks that the Company's proposed compounds may at any time be found to be unsafe or ineffective for the indications under clinical test and that clinical studies may at any point be suspended or take substantially longer than anticipated to complete. As discussed in the Company's Securities and Exchange Commission filings, the Company's proposed products will require additional research, lengthy and costly clinical testing and regulatory approval. AMPAKINE compounds are investigational drugs and have not been approved for the treatment of any disease.